Publication Date
| In 2024 | 0 |
| Since 2023 | 0 |
| Since 2020 (last 5 years) | 0 |
| Since 2015 (last 10 years) | 1 |
| Since 2005 (last 20 years) | 1 |
Descriptor
| Autism | 1 |
| Behavior Problems | 1 |
| Best Practices | 1 |
| Correlation | 1 |
| Drug Therapy | 1 |
| Drug Use | 1 |
| Foreign Countries | 1 |
| Guidance | 1 |
| Health Personnel | 1 |
| Health Services | 1 |
| Intellectual Disability | 1 |
| More ▼ | |
Source
| British Journal of Learning… | 1 |
Author
| Bonell, Simon | 1 |
| Nancarrow, Thomas | 1 |
| Rencher, Joshua | 1 |
| Shankar, Rohit | 1 |
| Wilcock, Mike | 1 |
| Wolke, Tony | 1 |
Publication Type
| Journal Articles | 1 |
| Reports - Research | 1 |
Education Level
Audience
Location
| United Kingdom (England) | 1 |
Laws, Policies, & Programs
Assessments and Surveys
What Works Clearinghouse Rating
Peer reviewed
Direct linkNancarrow, Thomas; Rencher, Joshua; Wilcock, Mike; Bonell, Simon; Wolke, Tony; Shankar, Rohit – British Journal of Learning Disabilities, 2019
Background: Intellectual disability (ID) is associated with polypharmacy particularly off-label psychotropics for "challenging behaviour." NHS England introduced the "stopping over medication of people with a learning disability (LD), autism or both" (STOMP) initiative. As ID services are a professionally diverse group, it is…
Descriptors: Intellectual Disability, Learning Disabilities, Correlation, Drug Therapy
